12 / 88 resources displayed
-
Scientific Posters
Real time adaptive manufacturing - a new paradigm for personalized drug products in clinical development - AAPS 2015
This poster reports on a new real-time adaptive GMP manufacturing paradigm serving patient and study needs by delivering personalized drug products on demand.
-
Scientific Posters
Absorption, metabolism and excretion of [14C]-gemigliptin - ISSX 2016
Absorption, metabolism and excretion of [14C]-gemigliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans.
-
Scientific Posters
A Phase I, open-label, 2-Part study to establish absolute bioavailability - DMDG 2016
A Phase I, open-label, 2-Part study to establish absolute bioavailability and the ADME of evogliptin in healthy male subjects by light-label approach
-
Scientific Posters
A rapid formulation development and clinical testing program to evaluate the pharmacokinetics of a novel enabled formulation of abiraterone acetate - AAPS 2016
Following initial dosing, the Translational Pharmaceutics platform also allows GMP drug products to be made in real-time in response to interim analysis of clinical data, typically on a 7-14 day cycle.
-
Scientific Posters
Maximising the potential of amorphous spray-dried dispersions - APS 2016
Maximising the Potential of Amorphous Spray-Dried Dispersions to Enhance Clinical Bioavailability. Amorphous Dispersions (ADs) provide an effective approach to oral bioavailability improvement for poorly soluble compounds
-
Scientific Posters
Site of absorption of an oral formulation of semaglutide - ADA 2017
Absorption of oral peptide-based drug formulations is challenged by the fact that peptides are degraded in the stomach due to low pH and proteolytic enzymes, as well as by their limited permeability across the gastrointestinal epithelium.
-
Scientific Posters
A pharmacoscintigraphic study of the relationship between tablet erosion and pharmacokinetics of oral semaglutide - ADA 2017
When administered orally, peptide-based drugs are susceptible to degradation in the stomach due to exposure to low pH and proteolytic enzymes.
-
Scientific Posters
A randomised double-blind dose escalation study- ASCPT 2016
A randomised double-blind dose escalation study to evaluate the safety and dose response of subcutaneous administration of coversin in healthy subjects
-
Scientific Posters
Clinical Pharmacokinetics and Pharmacodynamics of ME-401 - AACR 2016
Clinical Pharmacokinetics and Pharmacodynamics of ME-401, an Oral, Potent and Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, Following Single Ascending Dose Administration to Healthy Volunteers
-
Case Studies
Pulmatrix
Breathing new life into Phase 1 trials. Quotient's approach is helping Pulmatrix to develop a range of inhaled dry powder chemical entities based on its iSPERSE™ technology to meet unmet medical needs in multiple respiratory diseases.
-
Case Studies
Corcept Therapeutics
An accelerated approach to clinical trials. Corcept Therapeutics is developing CORT125134, a promising candidate for the treatment of Cushing’s syndrome, a rare disorder associated with significant morbidity and mortality.
-
Case Studies
Clovis Oncology
Clovis Oncology has chosen Quotient’s drug product optimization approach for rociletinib, a promising oral candidate drug for the treatment of EGFR-resistant non-small cell lung cancer.